Last €18.60 EUR
Change Today -0.30 / -1.59%
Volume 0.0
MZN On Other Exchanges
Symbol
Exchange
Munich
NASDAQ GS
As of 2:11 AM 09/22/14 All times are local (Market data is delayed by at least 15 minutes).

medicines company (MZN) Snapshot

Open
€19.43
Previous Close
€18.90
Day High
€19.43
Day Low
€18.60
52 Week High
01/13/14 - €30.11
52 Week Low
08/4/14 - €17.03
Market Cap
1.2B
Average Volume 10 Days
5.0
EPS TTM
--
Shares Outstanding
65.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDICINES COMPANY (MZN)

medicines company (MZN) Related Businessweek News

No Related Businessweek News Found

medicines company (MZN) Details

The Medicines Company provides medical solutions for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for use in patients undergoing percutaneous coronary intervention; Recothrom, a human recombinant thrombin used as an aid to hemostasis; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; Minocin IV, an antibiotic for the treatment of infections due to gram-negative bacteria, including Acinetobacter species; and ready-to-use formulation of Argatroban for the treatment of thrombosis. Its products under development include Cangrelor, an intravenous small molecule antiplatelet agent for the prevention of platelet activation and aggregation; Oritavancin, an investigational intravenous antibiotic for the treatment of acute bacterial skin related infections; and IONSYS, a pre-registration stage product for the short-term management of acute postoperative pain. The company’s products under development also comprise Fibrocaps, which is used as an aid to stop bleeding during surgery; RPX-602 for the treatment of infections; MDCO-216, a novel biologic product to reverse atherosclerotic plaque development and reduce the risk of coronary events in patients with ACS; Carbavance, an antibiotic agent for the treatment of hospitalized patients with bacterial infections; and ALN-PCSsc, a subcutaneously administered RNA interference therapeutic for the treatment of hypercholesterolemia. In addition, it offers acute care generic products for use in the cardiovascular and neurocritical care; and promotes BRILINTA, an oral tablet antiplatelet medicine. The company has collaborations with Alnylam Pharmaceuticals, Inc. and AstraZeneca LP. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.

571 Employees
Last Reported Date: 03/3/14
Founded in 1996

medicines company (MZN) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $793.3K
President, Chief Financial Officer, Treasurer...
Total Annual Compensation: $569.3K
Chief Accounting Officer and Senior Vice Pres...
Total Annual Compensation: $398.2K
Compensation as of Fiscal Year 2013.

medicines company (MZN) Key Developments

The Medicines Company - Special Call

To discuss plans for launching ORBACTIV for injection

FDA Approves The Medicines Company's ORBACTIV(TM) (oritavancin) for Use in Acute Bacterial Skin and Skin Structure Infections

The Medicines Company announced that the U.S. Food and Drug Administration (FDA) has approved ORBACTIV(TM) (oritavancin) for injection for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSIs) caused by susceptible designated Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA). ORBACTIV is the first and only antibiotic approved by FDA to treat ABSSSIs with a single, once-only administration. Once fully infused over three hours, the ORBACTIV treatment regimen is complete for patients with skin infections caused by susceptible Gram-positive pathogens. ORBACTIV approval is based on the results of the SOLO I and SOLO II clinical studies which were randomized, double-blind, multicenter trials that evaluated a single 1,200 mg IV dose of ORBACTIV for the treatment of ABSSSI in 1,987 patients, and assessed a large subset of patients with documented MRSA infection (405 patients). These trials demonstrated non-inferiority for the primary and secondary endpoints evaluating 1,200 mg once-only IV ORBACTIV dose infusion, versus 7-to-10 days of twice-daily vancomycin (1 g or 15 mg/kg). The European Medicines Agency has accepted for review the Marketing Authorization Application (MAA) for ORBACTIV, for which the company is seeking approval for the treatment of complicated skin and soft tissue infections (cSSTI). A decision from the European Commission is expected during the first half of 2015.

The Medicines Company - Special Call

To discuss the ORBACTIV approval

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MZN:GR €18.60 EUR -0.30

MZN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $72.54 USD -0.56
CryoLife Inc $10.21 USD +0.07
Eli Lilly & Co $66.53 USD -0.06
GlaxoSmithKline PLC 1,449 GBp +12.50
Medicure Inc C$2.70 CAD +0.15
View Industry Companies
 

Industry Analysis

MZN

Industry Average

Valuation MZN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.2x
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDICINES COMPANY, please visit www.themedicinescompany.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.